June 15, 2016 News by Patricia Silva, PhD Merck Joins with HAPPYneuron to Add Cognitive Training Games to MSdialog Merck Biopharma Ā announced it has entered intoĀ aĀ partnership with a French subsidiary calledĀ HAPPYneuron,Ā and now hasĀ an exclusive license to that companyās cognitiveĀ remediation training program for multiple sclerosis (MS).Ā The program, a series of brain training games and exercises, will be made available to people needing itĀ throughĀ Merck’s MSdialog platform. An e-Health…
May 23, 2016 News by Patricia Silva, PhD #CMSC16 – EMD Serono’s Dr. Rick Munschauer Discusses Value of Annual Meeting With theĀ Consortium of Multiple Sclerosis Centers (CMSC) 2016 fast approaching, Multiple Sclerosis News TodayĀ sat down with a man of far-reaching interest in multiple sclerosis (MS) Ā ā Dr. Rick Munschauer, Vice President of Medical Affairs, Neurology and Immunology at…
September 16, 2015 News by Patricia Silva, PhD MS Patients and Healthcare Providers Report Success of MSdialog App in Tracking Disease An international research team recently reported that the web-based MSdialog appĀ is being adopted by bothĀ multiple sclerosis (MS) patients and healthcare providers. The study is entitled āPatient and Physician Perspectives on MSdialog, an Electronic PRO Diary in Multiple Sclerosisā and was published in the journal…
September 14, 2015 News by Patricia Silva, PhD Merck Prepares to File for European Marketing Authorization for Cladribine Tablets as a Multiple Sclerosis Therapy MerckĀ recently reported its intention to file for European registration of its product candidate forĀ relapsing multiple sclerosis – Cladribine, a synthetic anti-cancer agent able to suppress the immune system. Cladribine causesĀ relatively few side effects and results in very little non-target cell loss. Merck’s decision follows new findingsĀ and further characterization of…
September 16, 2014 News by Patricia Silva, PhD Merck Serono Awards ā¬1 Million at the Second Annual Grant for Multiple Sclerosis Innovation Biopharmaceutical companyĀ Merck Serono, a division of Merck, recently awardedĀ a total of ā¬1 million to the five winners of theĀ second annual Grant for Multiple Sclerosis Innovation (GMSI) at MS Boston 2014, the joint meeting of the Americas Committee for Treatment and Research in MS (ACTRIMS) and European Committee…